Skip to main content

Table 3 Budget impact of optimal choices for cervical cancer prevention in the Philippines

From: A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines

Options

TARGET POPULATION (5-yearly)

5 YEARS BUDGET in million Php (USD)

ANNUAL BUDGET in million Php (USD)

VIA

Vaccination (3-dose)

Pap Smear

VIA

Vaccination (3-dose)

Pap Smear

Total

8 % Pap (35–55)

-

-

941,758

-

-

471 (11.13)

909 (21.48)

182 (4.30)

8 % VIA (35–55)

941,758

-

-

94 (2.22)

-

-

471 (11.13)

94 (2.22)

80 % VIA (35–45)

5,597,648

-

-

560 (13.23)

-

-

2,799 (66.13)

560 (13.23)

80 % VIA (35–50)

7,663,312

-

-

766 (18.10)

-

-

3,832 (90.54)

766 (18.10)

80 % VIA (35–55)

9,417,584

-

-

942 (22.26)

-

-

4,709 (111.26)

942 (22.26)

80 % Vac 11 + 80 % VIA (35–45)

5,597,648

4,059,120

-

560 (13.23)

11,106 (262.40)

-

13,905 (328.53)

2,781 (65.71)

80 % Vac 11 + 80 % VIA (35–50)

7,663,312

4,059,120

-

766 (18.10)

11,106 (262.40)

-

14,937 (352.92)

2,987 (70.57)

80 % Vac 11 + 80 % VIA (35–55)

9,417,584

4,059,120

-

942 (22.26)

11,106 (262.40)

-

15,815 (373.66)

3,163 (74.73)

80 % Vac 11 + 80 % VIA (30–55)

15,704,480

4,059,120

-

1570 (37.09)

11,106 (262.40)

-

18,958 (447.92)

3,792 (89.95)